{
     "PMID": "27382013",
     "OWN": "NLM",
     "STAT": "MEDLINE",
     "DCOM": "20170509",
     "LR": "20180116",
     "IS": "1521-0111 (Electronic) 0026-895X (Linking)",
     "VI": "90",
     "IP": "3",
     "DP": "2016 Sep",
     "TI": "Characterization of a Novel M1 Muscarinic Acetylcholine Receptor Positive Allosteric Modulator Radioligand, [3H]PT-1284.",
     "PG": "177-87",
     "LID": "10.1124/mol.116.104737 [doi]",
     "AB": "Selective activation of the M1 muscarinic acetylcholine receptor (mAChR) via a positive allosteric modulator (PAM) is a new approach for the treatment of the cognitive impairments associated with schizophrenia and Alzheimer's disease. Herein, we describe the characterization of an M1 PAM radioligand, 8-((1S,2S)-2-hydroxycyclohexyl)-5-((6-(methyl-t3)pyridin-3-yl)methyl)-8,9-dihydro -7H-pyrrolo[3,4-hour]quinolin-7-one ([(3)H]PT-1284), as a tool for characterizing the M1 allosteric binding site, as well as profiling novel M1 PAMs. 8-((1S,2S)-2-Hydroxycyclohexyl)-5-((6-methylpyridin-3-yl)methyl)-8,9-dihydro-7H-p yrrolo[3,4-hour]quinolin-7-one (PT-1284 ( 1: )) was shown to potentiate acetylcholine (ACh) in an M1 fluorometric imaging plate reader (FLIPR) functional assay (EC50, 36 nM) and carbachol in a hippocampal slice electrophysiology assay (EC50, 165 nM). PT-1284 ( 1: ) also reduced the concentration of ACh required to inhibit [(3)H]N-methylscopolamine ([(3)H]NMS) binding to M1, left-shifting the ACh Ki approximately 19-fold at 10 muM. Saturation analysis of a human M1 mAChR stable cell line showed that [(3)H]PT-1284 bound to M1 mAChR in the presence of 1 mM ACh with Kd, 4.23 nM, and saturable binding capacity (Bmax), 6.38 pmol/mg protein. M1 selective PAMs were shown to inhibit [(3)H]PT-1284 binding in a concentration-responsive manner, whereas M1 allosteric and orthosteric agonists showed weak affinity (>30 muM). A strong positive correlation (R(2) = 0.86) was found to exist between affinity values generated for nineteen M1 PAMs in the [(3)H]PT-1284 binding assay and the EC50 values of these ligands in a FLIPR functional potentiation assay. These data indicate that there is a strong positive correlation between M1 PAM binding affinity and functional activity, and that [(3)H]PT-1284 can serve as a tool for pharmacological investigation of M1 mAChR PAMs.",
     "CI": [
          "Copyright (c) 2016 by The American Society for Pharmacology and Experimental",
          "Therapeutics."
     ],
     "FAU": [
          "Smith, Deborah L",
          "Davoren, Jennifer E",
          "Edgerton, Jeremy R",
          "Lazzaro, John T",
          "Lee, Che-Wah",
          "Neal, Sarah",
          "Zhang, Lei",
          "Grimwood, Sarah"
     ],
     "AU": [
          "Smith DL",
          "Davoren JE",
          "Edgerton JR",
          "Lazzaro JT",
          "Lee CW",
          "Neal S",
          "Zhang L",
          "Grimwood S"
     ],
     "AD": "Neuroscience and Pain Research Unit (D.L.S., J.R.E., S.N., S.G.) and Worldwide Medicinal Chemistry (J.E.D., L.Z.), Pfizer Inc., Cambridge, Massachusetts; Primary Pharmacology Group (J.T.L.) and Worldwide Medicinal Chemistry (C.-W.L.), Pfizer Inc., Groton, Connecticut Deborah.L.Smith@Pfizer.com. Neuroscience and Pain Research Unit (D.L.S., J.R.E., S.N., S.G.) and Worldwide Medicinal Chemistry (J.E.D., L.Z.), Pfizer Inc., Cambridge, Massachusetts; Primary Pharmacology Group (J.T.L.) and Worldwide Medicinal Chemistry (C.-W.L.), Pfizer Inc., Groton, Connecticut. Neuroscience and Pain Research Unit (D.L.S., J.R.E., S.N., S.G.) and Worldwide Medicinal Chemistry (J.E.D., L.Z.), Pfizer Inc., Cambridge, Massachusetts; Primary Pharmacology Group (J.T.L.) and Worldwide Medicinal Chemistry (C.-W.L.), Pfizer Inc., Groton, Connecticut. Neuroscience and Pain Research Unit (D.L.S., J.R.E., S.N., S.G.) and Worldwide Medicinal Chemistry (J.E.D., L.Z.), Pfizer Inc., Cambridge, Massachusetts; Primary Pharmacology Group (J.T.L.) and Worldwide Medicinal Chemistry (C.-W.L.), Pfizer Inc., Groton, Connecticut. Neuroscience and Pain Research Unit (D.L.S., J.R.E., S.N., S.G.) and Worldwide Medicinal Chemistry (J.E.D., L.Z.), Pfizer Inc., Cambridge, Massachusetts; Primary Pharmacology Group (J.T.L.) and Worldwide Medicinal Chemistry (C.-W.L.), Pfizer Inc., Groton, Connecticut. Neuroscience and Pain Research Unit (D.L.S., J.R.E., S.N., S.G.) and Worldwide Medicinal Chemistry (J.E.D., L.Z.), Pfizer Inc., Cambridge, Massachusetts; Primary Pharmacology Group (J.T.L.) and Worldwide Medicinal Chemistry (C.-W.L.), Pfizer Inc., Groton, Connecticut. Neuroscience and Pain Research Unit (D.L.S., J.R.E., S.N., S.G.) and Worldwide Medicinal Chemistry (J.E.D., L.Z.), Pfizer Inc., Cambridge, Massachusetts; Primary Pharmacology Group (J.T.L.) and Worldwide Medicinal Chemistry (C.-W.L.), Pfizer Inc., Groton, Connecticut. Neuroscience and Pain Research Unit (D.L.S., J.R.E., S.N., S.G.) and Worldwide Medicinal Chemistry (J.E.D., L.Z.), Pfizer Inc., Cambridge, Massachusetts; Primary Pharmacology Group (J.T.L.) and Worldwide Medicinal Chemistry (C.-W.L.), Pfizer Inc., Groton, Connecticut.",
     "LA": [
          "eng"
     ],
     "PT": [
          "Journal Article"
     ],
     "DEP": "20160705",
     "PL": "United States",
     "TA": "Mol Pharmacol",
     "JT": "Molecular pharmacology",
     "JID": "0035623",
     "RN": [
          "0 (Isoindoles)",
          "0 (PT-1284)",
          "0 (Pyridines)",
          "0 (Receptor, Muscarinic M1)",
          "N9YNS0M02X (Acetylcholine)",
          "VDR09VTQ8U (N-Methylscopolamine)"
     ],
     "SB": "IM",
     "MH": [
          "Acetylcholine",
          "Allosteric Regulation",
          "Animals",
          "Autoradiography",
          "CHO Cells",
          "Cricetinae",
          "Cricetulus",
          "Electrophysiological Phenomena",
          "Fluorometry",
          "HEK293 Cells",
          "Hippocampus/physiology",
          "Humans",
          "Isoindoles/*metabolism",
          "Kinetics",
          "Male",
          "Membranes/metabolism",
          "N-Methylscopolamine/metabolism",
          "Positron-Emission Tomography",
          "Pyridines/*metabolism",
          "*Radioligand Assay",
          "Rats, Sprague-Dawley",
          "Receptor, Muscarinic M1/*metabolism"
     ],
     "EDAT": "2016/07/07 06:00",
     "MHDA": "2017/05/10 06:00",
     "CRDT": [
          "2016/07/07 06:00"
     ],
     "PHST": [
          "2016/04/14 00:00 [received]",
          "2016/06/30 00:00 [accepted]",
          "2016/07/07 06:00 [entrez]",
          "2016/07/07 06:00 [pubmed]",
          "2017/05/10 06:00 [medline]"
     ],
     "AID": [
          "mol.116.104737 [pii]",
          "10.1124/mol.116.104737 [doi]"
     ],
     "PST": "ppublish",
     "SO": "Mol Pharmacol. 2016 Sep;90(3):177-87. doi: 10.1124/mol.116.104737. Epub 2016 Jul 5.",
     "term": "hippocampus"
}